Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$1.62B+201.68%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Dave Caspers
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Employees
- 22,350
- Beta
- 0.72
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 2.01
Financials
Revenue
$1.62B+201.7%Net Income
$16.90M-82.7%EBITDA
$71.98M+71.3%Free Cash Flow
$158.06MEPS (diluted)
$0.12+39.9%Shares Outstanding (diluted)
143.05M+88.3%Operating Expenses
$0.00Cash & Debt
$724.48MReturn of Capital
$13.03MRevenue by Segment (annual)
$6.32BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $6.32B | $135.81M | $0.96 |
| 2024 | $5.97B | $210.34M | $1.59 |
| 2023 | $5.41B | $50.29M | $0.35 |
| 2022 | $5.13B | $188.91M | $1.32 |
| 2021 | $4.87B | $154.26M | $1.08 |
| 2018 | $4.16B | $-143.02M | $-1.01 |
| 2017 | $3.00B | $-35.65M | $-0.25 |
| 2016 | $2.11B | $14.60M | $0.10 |
| 2015 | $2.03B | $-46.36M | $-0.33 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $1.42
- Implied price
- $12.76
- Return from $10.34
- 4.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $6.34 — -38.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 5 | 7 | 9 | 11 | 13 |
|---|---|---|---|---|---|
| -2.0% | -15.9% | -10.0% | -5.4% | -1.5% | 1.9% |
| 3.0% | -11.6% | -5.4% | -0.5% | 3.5% | 7.1% |
| 8.0% | -7.3% | -0.8% | 4.3% | 8.6% | 12.3% |
| 13.0% | -3.0% | 3.8% | 9.1% | 13.6% | 17.5% |
| 18.0% | 1.3% | 8.4% | 14.0% | 18.6% | 22.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
110+10.00%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·3d ago·Positive
Ardent Health Passed Its Health Check Ardent Health remains a 'buy' as shares are deeply undervalued despite recent profitability declines. ARDT revenue continues to grow, with management projecting $6.4–$6.7 billion for the year, but EBITDA and cash flow are expected to fall short of prior results. Professional fees pressured margins, but management anticipates this cost trend will moderate in the second half, signaling potential stabilization.
View source ↗ - Newszacks.com·19d ago·Negative
Is the Options Market Predicting a Spike in Ardent Health Stock? Investors need to pay close attention to ARDT stock based on the movements in the options market lately.
View source ↗ - Newszacks.com·53d ago·Neutral
Implied Volatility Surging for Ardent Health Stock Options Investors need to pay close attention to ARDT stock based on the movements in the options market lately.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $0.24 per share
Typical surprise +38.1% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$0.12 vs $0.18miss
- Tue, May 5$0.28 vs $0.18beat
- Wed, Mar 4$0.32 vs $0.35miss
- Wed, Nov 12$0.52 vs $0.42beat
- Tue, Aug 5$0.52 vs $0.30beat
- Tue, May 6$0.29 vs $0.21beat
Estimates and results for ARDT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ARDT officers and directors.
- Bought
- $526k
- Sold
- —
4 trades
0 trades
- Demichiei Robertbought
- Lumsdaine Alfredbought
- Webb Robert Thomasbought
- Webb Robert Thomasbought
96 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ARDT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.